Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-D rollover study of durvalumab in oncology
CTR20252725Phase 3Active
- Sponsor
- MedImmune
- Start
- Sep 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in bronchial carcinoma, transitional cell carcinoma (TCC), sponsored by MedImmune. Started Sep 2025; status: active.
02
Drugs
durvalumab
03
Conditions
bronchial carcinomatransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20252725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252725.